PD01.08. Optimizing Postoperative Systemic Therapy Following Neoadjuvant Chemoimmunotherapy and Resection for Locally Advanced Esophageal Cancer: A Multicenter Real-World Analysis
Clicks: 1
ID: 325685
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #63 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Neoadjuvant chemoimmunotherapy (nICT) followed by surgical resection has emerged as a standard approach for locally advanced esophageal cancer. However, the role and optimal modality of postoperative immunotherapy in patients who have already received immune checkpoint blockade remain uncertain, particularly outside the context of prospective trials. We sought to evaluate the impact of different adjuvant immunotherapy strategies on survival in a real-world, multicenter cohort. Methods We retrospectively analyzed 556 consecutive patients with locally advanced esophageal cancer who underwent nICT followed by curative-intent surgery across multiple centers. According to postoperative management, patients were classified into an observation cohort (n = 251) and an adjuvant immunotherapy cohort (n = 305). The latter was further stratified into two predefined strategies: postoperative chemoimmunotherapy (2–4 cycles of chemotherapy combined with immunotherapy; n = 164) and immunotherapy maintenance (continued immunotherapy with or without preceding chemotherapy; n = 141). Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan–Meier methods and compared across groups. Subgroup analyses were conducted based on pathological nodal status, tumor regression grade (TRG), and pathological response. Results In the overall population, postoperative immunotherapy was associated with a trend toward prolonged OS and DFS compared with observation, although the difference did not reach statistical significance. Notably, patients with pathological lymph node involvement (ypN+) and those demonstrating favorable tumor regression (TRG 0–1) appeared to derive greater benefit. When stratified by treatment strategy, short-course postoperative chemoimmunotherapy did not confer a survival advantage relative to observation. In contrast, immunotherapy maintenance was independently associated with improved OS and DFS, with the magnitude of benefit most evident among patients with ypN+ disease, non-pathological complete response, and TRG 0–1. Conclusion In patients receiving nICT followed by surgery for locally advanced esophageal cancer, the effect of postoperative immunotherapy varies according to therapeutic strategy and residual pathological risk. Maintenance immunotherapy, rather than short-course chemoimmunotherapy, was associated with superior survival outcomes, particularly in patients with residual nodal disease and favorable response to neoadjuvant therapy. These findings highlight the importance of individualized, risk-adapted postoperative treatment planning in the contemporary nICT era.
| Reference Key |
openalex_W7203877322
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yizhou Huang, Maohui Chen, Zhenyuan Yang, Taidui Zeng, Chun Chen, Bin Zheng |
| Journal | diseases of the esophagus : official journal of the international society for diseases of the esophagus |
| Year | 2026 |
| DOI |
10.1093/dote/doag077.078
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.